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ABSTRACT Nonmuscle cells have almost ubiquitously
evolved a mechanism to detect and prevent Ca21 store deple-
tion—store operated calcium entry. No such mechanism has,
as yet, been reported in cardiac myocytes. However, it is
conceivable that such a mechanism may play an important
role in cardiac Ca21 homeostasis to ensure the availability of
sufficient stored Ca21 to maintain normal excitation contrac-
tion coupling. We present data that confirms the presence of
a mechanism that is able to monitor the Ca21 load of the SR
and initiate a signaling process to accelerate Ca21 uptake by
the SR when store depletion is detected. Depletion of SR Ca21
activates a protein kinase, the principal SR substrate of which
is phospholamban. Phosphorylation of this SR protein pro-
motes Ca21 pump activity and therefore store refilling. Fur-
thermore, a protein kinase activity associated with the SR that
is inhibited by Ca21 ions has been identified. We have
measured lumenal [Ca21] by using a fluorescent Ca21 indi-
cator and found that by initiating Ca21 uptake and increasing
Ca21 load, we can inhibit the protein kinase activity associated
with the SR. This confirms that a protein kinase, that is
regulated by lumenal [Ca21], has been identified and repre-
sents part of a previously unidentified signalling cascade. This
local feedback mechanism would allow the myocyte to detect
and prevent SR Ca21 load depletion.
The calcium required for cardiac muscle contraction is derived
from two sources, the intracellular store [the sarcoplasmic
reticulum (SR)] that represents a finite reserve, and the
extracellular milieu, which is effectively infinite. The quanti-
tative importance of each of these sources in excitation con-
traction coupling is the inverse of their size. The SR contrib-
utes '75% of the Ca21 for each contraction (variable with
animal species) with the remainder entering from the extra-
cellular environment (1). The maintenance of the intracellular
Ca21 store, suitably filled with Ca21, is a prerequisite for
excitation contraction coupling, and is achieved by the appro-
priate competition between Ca21 transport systems of the SR
and plasma membrane (1). In many other cell types the
intracellular Ca21 store also performs an important function.
Ca21 release enables the cell to effectively translate extracel-
lular signals into functional responses. To guard against Ca21
store depletion and loss of this capability, cells have evolved a
mechanism that allows constant replenishment of the Ca21
store. Store operated Ca21 entry initiated by retrograde
signaling pathways have been described in a wide variety of cell
types, including smooth muscle cells and nonmuscle cells
(2–4). The exact nature of the retrograde signal remains a
matter of some debate. One example, however, is a protein
phosphatase in human platelets that is responsive to the Ca21
content of platelet stores and modifies the phosphorylation
status of targets in response to store depletion (5). A second
example may involve the mammalian homologue of the seriney
threonine kinase IRE1 (6). Inhibition of Ca21 uptake by
intracellular Ca21 stores of Chinese hamster ovary cells results
in the increased expression of the molecular chaperone grp78
(6), an effect that is exaggerated by expression of the yeast
kinase IRE1. By analogy, the Ca21 concentration within the
lumen of the SR of cardiac muscle may control kinasey
phosphatase enzymes and thereby influence the rate of Ca21
accumulation by the store. This could serve to safeguard the
SR from progressive Ca21-loss if the Ca21-transport systems of
the plasma membrane and SR were not balanced appropri-
ately. Phospholamban represents a plausible target in this
hypothesis; normally an inhibitor of SR Ca21 pump activity,
phosphorylation of phospholamban in response to Ca21 store
depletion would be expected to accelerate Ca21-uptake by the
SR (7) and facilitate store refilling. In the present study,
experimental evidence is provided in support of this sugges-
tion. First, freshly isolated cardiac myocytes (from the rat)
responded to SR Ca21 depletion by phosphorylating phospho-
lamban on Ser-16. Second, a protein kinase that copurifies
with the SR is active at low [Ca21] (#3 mM), but inhibited by
high [Ca21] ($30 mM). This activity represents a potential
candidate mediating the myocyte response to Ca21 store
depletion. Finally, we have demonstrated that the site of this
regulation by Ca21 is from the lumenal aspect of the SR
membrane ([Ca21]L). Manipulating lumenal Ca21 alters phos-
pholamban phosphorylation in a manner consistent with our
hypothesis, i.e., at steady-state loading, which represents
[Ca21]L of 35 mM phospholamban phosphorylation is inhib-
ited. Collapse of the Ca21 gradient and a return to low [Ca21]L
(3 mM) results in a concomitant increase in phospholamban
phosphorylation.
EXPERIMENTAL PROCEDURES
Materials. Cardiac SR vesicles were prepared as described
in Li et al. (8), phospholamban antibodies as described in
Drago and Colyer (9). The catalytic subunit of protein kinase
A was purified from bovine heart according to Peters et al.
(10). The synthetic peptide PLl919Y (RSAIRRASTIEY) was
purchased from Neosystem (Strasbourg, France) and used as
received ('80% pure).
Ca21 Store Depletion in Cardiac Myocytes. Ventricular
myocytes were isolated from adult Wistar rats ('250 g as
described in ref. 11), loaded with Fura-2AM (Molecular
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Probes, 5 mM for 15 min at room temperature), and superfused
with physiological saline solution (11) in a perfusion chamber
mounted on an inverted microscope at room temperature
('22°C). The cells were electrically stimulated (0.5 Hz).
Myocytes were illuminated at 340 nm and 380 nm, alternately,
and the emission at 510 nm from a single cell was recorded and
subsequently expressed as the ratio of that generated by
340y380 excitation. The Ca21-content of the SR was assessed
by challenge with 10 mM caffeine (12). Once control data had
been captured from individual cells, the suspension was ex-
posed to sarcoplasmicyendoplasmic reticulum Ca21-ATPase
inhibitors [thapsigargin (Tg, 2.5 mM), 2,5-di-(t-butyl)-1,4-
hydroquinone (t-BHQ, 30 mM), and cyclopiazonic acid (CPA,
50 mM)] for 15 min. The SR Ca21 content was assessed by
challenge with 10 mM caffeine after 15 min exposure to drug.
Phospholamban Phosphorylation in Response to Store De-
pletion. Rat ventricular myocytes were isolated as described in
ref. 11 and resuspended at a density of '105 cellsyml in 5 mM
Hepes (pH 7.3), 113 mM NaCl, 1 mM Na2HPO4, 1 mM
MgSO4, 5 mM KCl, 10 mM glucose, 20 mM Na acetate, 5
unitsyml insulin, 0.75 mM CaCl2. A single sarcoplasmicy
endoplasmic reticulum Ca21-ATPase 2 inhibitor (2.5 mM Tg,
30 mM t-BHQ, or 50 mM CPA) was added to individual cell
suspensions, and dimethylsulfoxide (0.5% by volume) was
added to control suspensions. The cells were agitated and
electrically stimulated (0.5 Hz, 80 V) for 5 min. The reaction
was stopped by the addition of Laemmli sample buffer (13) and
the site-specific phosphorylation of phospholamban (on Ser-16
and Thr-17) was determined by Western blot analysis (9) by
using 10,000 cells per observation.
In Vitro Phosphorylation of Phospholamban. Phosphoryla-
tion was performed at 30°C in the absence and presence of 200
nM c-protein kinase A in 50 mM histidine (pH 7.0), 5 mM
MgSO4, 6.25 mM NaF, 1 mM vanadate, 1 mM EGTA, 2 mM
A23187, 0.5 mgyml cardiac SR, 0.1 mM [g32P]-ATP ('100
cpmypmol), and CaCl2 to achieve free Ca21 concentrations of
3, 30, 300, and 3,000 mM. The phosphorylation reaction was
terminated by the addition of Laemmli sample buffer (13) and
SR proteins (10 mg) separated by SDSyPAGE (13).
Peptide Phosphorylation and Dephosphorylation. Phos-
phorylation of the synthetic peptide RSAIRRASTIEY.amide
(PL919Y, 14 mM) was performed in 50 mM histidine (pH 7.0),
5 mM MgSO4, 0.25 mM Tg, 2 mM A23187, 0.2 mgyml cardiac
SR, and 0.1 mM [g32P]-ATP ('100 cpmypmol) with either 3
mM or 3 mM CaCl2. The reaction was terminated by spotting
onto P81 phosphocellulose paper (Whatman) and washing in
1% phosphoric acid as described (14). Once dry, the papers
were scintillation counted in Emulsifier-safe (Canberra–
Packard). Dephosphorylation of PL919Y (140 mM) was ex-
amined following the phosphorylation of peptide at low Ca21
as described above with the assistance of 50 nM c-protein
kinase A. Phosphorylation was terminated by the addition of
1 mM PKI(5–22 amide) inhibitor peptide (15) (effective
against both enzymes at this concentration), plus 3 mM or 3
mM CaCl2. Dephosphorylation samples were collected and
processed as described above.
Measurement of [Ca21]L. Cardiac SR vesicles were removed
from preparation buffer by centrifugation at 4,000 rpm for 2
min. The pellet was resuspended in buffer A (sucrose 150
mMyPEG 5% (wtyvol)yKCl 50 mMyHepes 10 mM, pH 7.0).
Vesicles were then incubated with 10 mM Magfura-5 AM
(Molecular Probes) for 120 min at 4°C. Loaded vesicles were
harvested by centrifugation (as above) and washed twice in
buffer A before being resuspended in buffer A at a final
concentration of 2 mgyml. An excitation scan from 250–450
nm was used to determine success of dye loading (see Fig. 4).
Fluorescent measurements were performed on a Perkin–
Elmer LS50B luminescent spectrophotometer, using a filter
wheel to alternate between the two excitation wavelengths of
340 and 380 nm. Emission was measured at 510 nm. Ca21
uptake assay composition was routinely 1.5 mls; buffer B (75
mM sucrosey2.5% PEG (wtyvol)y25 mM KCly5 mM Hepes,
pH 7.0) and Magfura-5 loaded cardiac SR vesicles 67 mgyml.
Calcium uptake was initiated by addition of MgzATP (1.5
mM), assays were performed routinely at 30°C.
Phosphorylation of Phospholamban During Ca21 Uptake
and Release. Ca21 uptake into SR vesicles was performed in
parallel with the preceding section by addition of 1.5 mM
MgzATP to a suspension of vesicles (67 mgyml) in buffer B at
30°C. Samples were removed at various times and quenched in
Laemmli sample buffer (13). The phosphorylation status of
phospholamban was examined by SDSyPAGE and Western
blot analysis as described above.
RESULTS AND DISCUSSION
Interested in the signaling events triggered by Ca21 store
depletion in many cells, we sought to investigate the possibility
of an analogous process occurring in cardiac muscle. Our
proposal was that manipulation of the phosphorylation status
of phospholamban would be an appropriate response to the
depletion of Ca21 from the SR. We would anticipate an
increase in the phosphorylation of phospholamban, because
this would promote store refilling through increased Ca21
ATPase activity. To evaluate this hypothesis we first investi-
gated the response of a population of freshly isolated rat
cardiac myocytes to Ca21 store depletion. The SR was depleted
of Ca21 by treating cells with three structurally dissimilar Ca21
ATPase inhibitors, Tg, t-BHQ, and CPA. Fig. 1 illustrates the
effectiveness of this strategy: Ca21 transients from individual
rat ventricular myocytes (evoked by electrical stimulation)
were of uniform amplitude and short duration (Fig. 1 a, c, and
e). The Ca21 content of the SR was determined by exposure
to 10 mM caffeine (12, 16). This maneuver opens the Ca21
release channels in the SR (17) and mobilizes stored Ca21. The
Ca21 transient evoked by caffeine was larger than that arising
from electrical stimulation, indicative of a large amount of
Ca21 mobilized from the SR. The effects of caffeine were fully
reversible. Removal of caffeine solutions and restoration of
electrical stimulation was seen to refill the SR back to steady
state Ca21 transient levels. Exposure of the myocytes to each
of the three SR Ca21 pump inhibitors Tg (18) (2.5 mM, Fig. 1b),
t-BHQ (19) (30 mM, Fig. 1d), or CPA (20) (50 mM, Fig. 1f )
decreased the amplitude and increased the duration of the
Ca21 transient, consistent with inhibition of uptake by the SR.
This was accompanied by a small increase in diastolic [Ca21].
Under these conditions caffeine mobilizes little or no calcium
after 15-min exposure to these drugs (Fig. 1 b, d, and f ),
confirming depletion of SR Ca21 stores. According to our
hypothesis a coincident increase in phospholamban phosphor-
ylation would be anticipated.
The effect of store depletion on the phosphorylation of
Ser-16 of phospholamban was measured by using polyclonal
antibodies specific for this phosphorylation site (9). These
antibodies are wholly specific for phospholamban phosphor-
ylated at this site and facilitate immunodetection of the
phosphoprotein in whole-cell extracts. Rat cardiac myocytes
exhibit low basal phosphorylation of phospholamban on Ser-
16; this was increased dramatically on exposure of the cells to
the b-adrenergic agonist, isoprenaline (Fig. 2, Con and Iso). A
similar dramatic increase in the phosphorylation of phospho-
lamban was provoked by depletion of the SR Ca21 stores by 5
min exposure to each of the three Ca21 pump inhibitors [Fig.
2, Tg (2.5 mM), BHQ (30 mM), CPA (50 mM)]. The identical
effect of the three Ca21 pump inhibitors suggest that the
phosphorylation of phospholamban was provoked by their
common action, i.e., Ca21 pump inhibition and the subsequent
depletion of Ca21 stores. These data were reproduced in five
other experiments with rat ventricular myocytes and a sixth
with ferret ventricular myocytes (although not all drugs were
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used in all experiments). No change in Thr-17 phosphorylation
of phospholamban was observed as a result of store depletion
(data not shown). The small rise in diastolic Ca21 produced by
Ca21 pump inhibitors (Fig. 1) was not responsible for the
increasing Ser16 phosphorylation (in experiments of Fig. 2),
because a similar elevation of cytoplasmic Ca21, achieved by
raising extracellular [Ca21] (21), was without effect on phos-
pholamban phosphorylation (data not shown). Thus, depletion
of the Ca21 store provides the signal to increase the phos-
phorylation of phospholamban. This in turn would promote
refilling of the Ca21 store through stimulation of Ca21 pump
activity (7).
The time course of Ca21 loss from the SR (illustrated by a
progressive reduction in the amplitude of the Ca21 transient)
upon exposure to sarcoplasmicyendoplasmic reticulum Ca21-
ATPase 2 inhibitors was very similar to that of the increase in
Ser-16 phosphorylation. Negretti et al. (12) demonstrated that
Tg (2.5 mM) reduced the caffeine-induced Ca21 mobilization
of Ca21 from the SR of rat ventricular myocytes (which is
believed to equate to SR load) by '50% after 2 min. In our
experiments Tg (2.5 mM) induced phosphorylation of phos-
pholamban was first evident at 3 min (data not shown). Thus
the signaling process that conveys the lumenal Ca21 status to
phospholamban is activated upon partial loss of Ca21 from the
SR, and may be an important control point to balance the
Ca21-sequestration activity of the SR with those of the sarco-
lemma.
Identification of a State of Filling Kinase (SOF Kinase).
The next step in this investigation was to identify enzymes
involved in mediating the phosphorylation of phospholamban
in response to Ca21 store depletion. In the first series of
experiments we sought to determine whether the candidate
enzymes were associated with cardiac SR vesicles. Phosphor-
ylation of phospholamban, catalyzed by enzymes associated
with SR vesicles was investigated as a function of [Ca21]. SR
vesicles are generally of right side out orientation (22), there-
fore a Ca21 ionophore (A23187) was included in these exper-
iments to facilitate manipulation of lumenal as well as cytosolic
[Ca21]. The phosphorylation of phospholamban was observed
at low [Ca21] (3 mM) upon addition of ATP, but was inhibited
progressively as the [Ca21] rose (30–3,000 mM) (Fig. 3A).
Under these conditions phosphorylation of phospholamban
was on Ser-16 exclusively (data not shown) as had been the case
in vivo (Fig. 2). Other SR proteins phosphorylated in these
experiments were unaffected by titration of Ca21 (data not
shown). Thus the phosphorylation of phospholamban by en-
zyme(s) associated with the SR was inhibited by high [Ca21].
The concentration dependence of this phenomenon is inap-
propriate for cytoplasmic Ca21, but within the range of
measured [Ca21]L found in the literature, which vary from 12
mM to 2 mM (23–26).
Two separate mechanisms could account for the reduced
phosphorylation of phospholamban at high [Ca21]. Either the
inhibition of a protein kinase or the activation of a phosphatase
could underlie these observations. The phosphorylation of a
synthetic peptide derived from the primary sequence of phos-
pholamban (residues 9–19 plus a carboxy terminal tyrosine
amide, refs. 9 and 27) was used to identify which of these
enzymes in cardiac SR was Ca21 sensitive. A Ca21 ionophore
(A23187) was included in the assay to ensure manipulation of
both lumenal and extravesicular [Ca21]. The peptide was
phosphorylated by an SR kinase at Ser-16; and the rate of
phosphorylation was inhibited by high [Ca21] (3 mM; Fig. 3C).
In contrast, dephosphorylation of this phosphopeptide (which
had previously been phosphorylated by protein kinase A) by
the SR phosphatase was slow and Ca21 insensitive (Fig. 3D).
These data identify a kinase as the Ca21 responsive element of
this process. The site of phosphorylation of phospholamban
was identified as Ser-16 (using a combination of phos-
phoamino acid analysis and phosphorylation site specific an-
tibodies; ref. 9), which is noteworthy because this site can be
phosphorylated by cyclic AMP-dependent kinase (27). How-
FIG. 1. Depletion of Ca21 from the SR of rat ventricular myocytes
by exposure to Ca21-pump inhibitors. The intracellular [Ca21] of
individual rat ventricular myocytes (11) was measured by Fura-2
fluorescence ratio before (a, c, and e) and during (b, d, and f ) exposure
to Ca21-pump inhibitors. Electrical stimulation of control cells in
physiological saline solution generated Ca21-transients of regular
amplitude and short duration. The cessation of electrical stimulation
and application of 10 mM caffeine (n) provoked release of Ca21 from
the SR detected by a large rise in the Fura-2 fluorescence ratio (a, c,
and e). Removal of caffeine and resumption of electrical stimulation
facilitated refilling of the SR and recovery of the peak amplitude of the
Ca21-transient to control levels. Exposure of the cells to a Ca21-pump
inhibitor for 15 min [b, 2.5 mM Tg; d, 30 mM t-BHQ (BHQ); f, 50 mM
CPA] caused loss of Ca21 from the SR that resulted in a reduction in
the Ca21-transient size observed upon electrical stimulation, and
ablation or massive attenuation of the Ca21-transient induced by
caffeine challenge (n). A small rise in diastolic Ca21 accompanied
exposure to these drugs. Each row of the figure shows Fura-2
fluorescence before and after 15-min exposure to the SR Ca21-pump
inhibitor in the same cell.
FIG. 2. Stimulation of phospholamban phosphorylation on Ser-16
by depletion of Ca21 from the SR of cardiac myocytes. The site-specific
phosphorylation of phospholamban was measured by using antibodies
specific to the phosphoprotein (9) following exposure of rat ventricular
myocytes to Ca21-pump inhibitors or the b-agonist, isoprenaline. Rat
ventricular myocytes (1.1 3 105yml, ref. 21) were exposed to 0.5%
dimethylsulfoxide (control, Con), 2.5 mM Tg (TG), 30 mM t-BHQ
(BHQ), 50 mM CPA, or 200 nM isoprenaline (Iso) for 5 min. Total cell
protein (10,000 cells) was resolved by SDSyPAGE (13) and transferred
to poly(vinylidene difluoride) membrane (9). The phosphorylation of
phospholamban on Ser-16 was determined by using a phosphorylation
site-specific antibody (9), developed by using an enhanced chemilu-
minescent substrate, and the region of the autoradiograph containing
phospholamban is shown. Similar results have been obtained in six
experiments with rat and ferret myocytes.
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ever, Ser-16 phosphorylation of phospholamban by protein
kinase A was Ca21 insensitive (Fig. 3B). The kinase cannot be
Cam kinase II, because this enzyme phosphorylates phospho-
lamban on Thr-17 exclusively. Neither is it protein kinase C;
this enzyme’s preferred site of phosphorylation is Ser-10.
Furthermore, protein kinase C is unaffected by protein kinase
I and microsystin, both of which inhibit SOF kinase. Thus a
kinase that is distinct from PKA and PKC is associated with
cardiac SR and represents a potential candidate mediating the
response to Ca21 store depletion in cardiac myocytes. The
Ca21 profile of the kinase would tend to preclude regulation
by cytosolic Ca21, because even during a Ca21 transient, the
[Ca21] would barely reach concentrations required to cause its
inhibition. However, because both lumenal and cytosolic Ca21
were manipulated in the experiment of Fig. 3, it is possible that
the inhibitory effects of high Ca21 were achieved from the
lumenal aspect of the SR. To investigate the site of regulation
further, we investigated the correlation between lumenal
[Ca21] and phospholamban phosphorylation. Intravesicular
Ca21 was measured by using the Ca21 indicator Magfura-5.
Incubation of the membrane permeable form (acetoxymeth-
ylester) with cardiac SR vesicles resulted in significant dees-
terification of the dye. Thus loading of vesicles with the Ca21
responsive form was clearly shown by a strong fluorescence
signal in the excitation spectrum 250–450 nm (Fig. 4A).
Addition of Mn21 (20 mM) caused quenching of the extracel-
lular signal (Fig. 4B). This was repeated in all experiments.
Permeabilizing the vesicular membrane by introducing iono-
mycin in the presence of Mn21 resulted in almost complete
quench (Fig. 4C), indicating that the majority ('80%) of the
fluorescent signal originated from within the membrane ves-
icles, i.e., from dye trapped in the lumen.
Calibration of Magfura-5. The response of Magfura-5 to
[Ca21] in our system was markedly nonlinear. The method of
Loomis-Husselbee and Dawson (29) was used to calibrate the
dye. A line of best fit to the response of the dye to a stepwise
increase in free [Ca21] was used to derive an empirical
relationship between fluorescence and [Ca21] (Fig. 5). This
equation was then applied to raw fluorescence data to convert
to [Ca21]. Addition of Ca21 (to a final concentration of 1 mM)
to a standard uptake assay, indicated a lumenal [Ca21] of 100
mM. This represents the extent of passive loading. However,
introduction of ionomycin results in a measured [Ca21] of 1
mM, correctly reflecting the free [Ca21] of the assay. There-
fore, application of the experimentally derived equation is an
accurate method of determining [Ca21].
[Ca21]L Following Active Ca21 Transport. Calcium uptake
into Magfura-5 loaded vesicles was initiated by the addition of
FIG. 3. Inhibition of phospholamban phosphorylation at high
Ca21. The phosphorylation of phospholamban in SR vesicles prepared
from canine heart (8) was catalyzed by an endogenous kinase (A) or
200-nM cAMP-dependent protein kinase (B) at various free Ca21
concentrations in the presence of A23187 (2 mM) for the times
indicated. Phosphoproteins (10 mg) were separated by SDSy15%
PAGE (13) and an autoradiograph of the region of the gel containing
phospholamban displayed. These data were reproduced in six separate
experiments by using different SR preparations. The phosphorylation
(C) and dephosphorylation (D) of an exogenous synthetic peptide
substrate derived from the sequence of phospholamban
(9RSAIRRASTIE19Y, single letter codes) was performed at either 3
mM (}) or 3 mM (n) CaCl2 in the presence of A23187 (2 mM) by
enzymes associated with the SR vesicles (see Materials and Methods).
Data shown are typical of four independent experiments.
FIG. 4. Excitation wavelength scans indicate substantial lumenal
de-esterification of Magfura-5 AM in canine cardiac SR vesicles.
Vesicles were incubated with Magfura-5 AM (10 mM) for 120 min at
4°C. Each assay consists of 100 mg of protein in 1.5 ml of assay buffer
(150 mM sucrosey50 mM KCly5% PEGy10 mM Hepes, pH 7.0).
Assays were performed at 30°C in a stirred cuvette. Traces describe
excitation scans from 260–450 nm measuring emission at 510 nm; (a)
Control; (b) addition of 20 mM Mn21 (to quench external Magfura-5);
(c) Addition of ionomycin (5 mM) plus Mn21 (50 mM). The ion
selectivity of ionomycin necessitates an increase in [Mn21] to observe
rapid quenching of lumenal Magfura-5.
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MgzATP (1.5 mM). After a rapid increase in lumenal [Ca21],
a steady-state loading of '35 mM was achieved and maintained
after 10 min (Fig. 6B). Tg released '70% of sequestered Ca21
(Fig. 6B, trace i) and addition of Tg before ATP resulted in no
significant uptake (Fig. 6B, trace ii), confirming the majority
of Ca21 uptake was into SR vesicles. Extravesicular [Ca21] in
this experiment would be '2.5 mM, a condition that supports
full SR kinase activity in vitro. However, if the effect of Ca21
is manifest from the SR lumen, then we would expect some
inhibition of SOF kinase activity at this [Ca21]L ('35 mM; Fig.
3A). Cardiac SR vesicles not loaded with Magfura-5 were
treated in the same way and used in the standard uptake assay.
Calcium uptake was again initiated by the addition of MgzATP.
Aliquots of assay medium (7.5 mg protein) were removed at
several points before and after the addition of MgzATP and
quenched by using Laemmli sample buffer (13). Fig. 6A
describes the phosphorylation of phospholamban during the
course of uptake. The level of phospholamban phosphoryla-
tion is low before the addition of MgzATP. On addition of
MgzATP an increase in phosphorylation is observed, which is
consistent with our hypothesis, because the vesicles at this
point would contain a low [Ca21]. As steady state was achieved
('10 min of uptake, Fig. 6B, trace i) and maintained, a gradual
decrease in phospholamban phosphorylation is observed (Fig.
6A, 209, 259). When [Ca21]L is reduced to 2.5 mM following
introduction of ionomycin an increase in phospholamban
phosphorylation was observed (Fig. 6A, 309, 359) consistent
with activation of the SR kinase (SOF kinase) in response to
Ca21 store depletion. Keeping [Ca21]L low by adding ionomy-
cin and MgzATP simultaneously results in SOF kinase activity
and a high level of phospholamban phosphorylation through-
out the time course of Ca21 uptake (not shown). Thus, [Ca21]L
has been directly measured in intact vesicles and manipulations
of [Ca21]L have resulted in the predicted changes in the
phosphorylation of phospholamban. Therefore, a direct causal
link between [Ca21]L and phospholamban phosphorylation
has been established, indicating that SOF kinase is indeed
regulated at the lumenal face of the SR membrane.
In conclusion, cardiac myocytes increase phospholamban
phosphorylation in response to store depletion. A phospho-
lamban kinase associated with cardiac SR vesicles and sensitive
to high Ca21 has been identified. Furthermore, loading Mag-
fura-5 into the lumen of these SR vesicles has enabled mea-
surement of active Ca21 transport, a [Ca21]L of '35 mM has
been observed. This figure is unlikely to reflect SR [Ca21]L in
vivo (see ref. 30), however, has allowed us to determine the site
of SOF kinase regulation. Measurement of the time course of
phospholamban phosphorylation during active Ca21 transport
indicated inhibition of SOF kinase activity when [Ca21]L rose
to 35 mM. This inhibition is consistent with both the Ca21
profile of SOF kinase activity (Fig. 3) and the time taken to
reach steady state Ca21 uptake ('10 min; Fig. 6B, trace i). This
evidence strongly supports the presence of a local feedback
mechanism in cardiac SR. Depletion of Ca21 load activates
SOF kinase, which in turn phosphorylates phospholamban. In
its phosphorylated state phospholamban can no longer exert
its inhibitory influence on sarcoplasmicyendoplasmic reticu-
lum Ca21-ATPase 2, therefore an increase in Ca21 pump
activity promotes the refilling of the Ca21 store.
FIG. 5. Calibration of Magfura-5 fluorescence with [Ca21]. Mag-
fura-5 loaded cardiac SR vesicles in a standard uptake assay were
permeabilized by ionomycin (5 mM). Free [Ca21] was manipulated by
using EGTA.Ca21 buffering. EGTA (50 mM) was included in each
assay followed by the addition of varying concentrations of Ca21
(determined by the computer program of ref. 31), depending on the
required free [Ca21] (1 mM–5 mM). Changes in the 340 nmy380 nm
ratio were calculated from excitation wavelength scans for each [Ca21]
and plotted against free [Ca21]. An equation was then derived from
the line of best fit (Microsoft EXCEL).
FIG. 6. Calcium uptake into canine cardiac SR vesicles; Control of
phospholamban phosphorylation by lumenal [Ca21]. The fluorescence
change of lumenal Magfura-5 on addition of MgzATP was measured.
Conversion of raw fluorescence data by application of the experimen-
tally determined equation shows a steady-state loading of '35 mM
Ca21. (B, trace i) Addition of Mg.ATP (1.5 mM) at 100 s; addition of
Tg (2 mM) at 900 s. (B, trace ii) Addition of Tg (2 mM) at 30 s; addition
of MgzATP (1.5 mM) at 100 s. (A) In parallel, aliquots of assay medium
(7.5 mg protein) were removed at several points before and after the
addition of MgzATP and quenched by using Laemmli sample buffer
(13). Proteins were separated by using SDSyPAGE and phospholam-
ban phosphorylation on Ser-16 was determined by using Western blot
analysis (see Materials and Methods).
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